Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 408

1.

Effectiveness of Stress-Reducing Interventions on the Response to Challenges to the Immune System: A Meta-Analytic Review.

Schakel L, Veldhuijzen DS, Crompvoets PI, Bosch JA, Cohen S, van Middendorp H, Joosten SA, Ottenhoff THM, Visser LG, Evers AWM.

Psychother Psychosom. 2019 Aug 6:1-13. doi: 10.1159/000501645. [Epub ahead of print] Review.

2.

Radiological Signs of Latent Tuberculosis on Chest Radiography: A Systematic Review and Meta-Analysis.

Uzorka JW, Wallinga J, Kroft LJM, Ottenhoff THM, Arend SM.

Open Forum Infect Dis. 2019 Jul 1;6(7). pii: ofz313. doi: 10.1093/ofid/ofz313.

3.

Two-Hit in vitro T-Cell Stimulation Detects Mycobacterium tuberculosis Infection in QuantiFERON Negative Tuberculosis Patients and Healthy Contacts From Ghana.

Adankwah E, Lundtoft C, Güler A, Franken KLMC, Ottenhoff THM, Mayatepek E, Owusu-Dabo E, Phillips RO, Nausch N, Jacobsen M.

Front Immunol. 2019 Jul 3;10:1518. doi: 10.3389/fimmu.2019.01518. eCollection 2019.

4.

Whole-blood transcriptomic signatures induced during immunization by chloroquine prophylaxis and Plasmodium falciparum sporozoites.

Tran TM, Bijker EM, Haks MC, Ottenhoff THM, Visser L, Schats R, Venepally P, Lorenzi H, Crompton PD, Sauerwein RW.

Sci Rep. 2019 Jun 10;9(1):8386. doi: 10.1038/s41598-019-44924-7.

5.

Harnessing donor unrestricted T-cells for new vaccines against tuberculosis.

Joosten SA, Ottenhoff THM, Lewinsohn DM, Hoft DF, Moody DB, Seshadri C; Collaboration for Tuberculosis Vaccine Discovery - Donor-Unrestricted T-cells Working Group, Bill and Melinda Gates Foundation.

Vaccine. 2019 May 21;37(23):3022-3030. doi: 10.1016/j.vaccine.2019.04.050. Epub 2019 Apr 27. Review.

6.

Oxidized low-density lipoprotein (oxLDL) supports Mycobacterium tuberculosis survival in macrophages by inducing lysosomal dysfunction.

Vrieling F, Wilson L, Rensen PCN, Walzl G, Ottenhoff THM, Joosten SA.

PLoS Pathog. 2019 Apr 18;15(4):e1007724. doi: 10.1371/journal.ppat.1007724. eCollection 2019 Apr.

7.

Immunometabolic Signatures Predict Risk of Progression to Active Tuberculosis and Disease Outcome.

Duffy FJ, Weiner J 3rd, Hansen S, Tabb DL, Suliman S, Thompson E, Maertzdorf J, Shankar S, Tromp G, Parida S, Dover D, Axthelm MK, Sutherland JS, Dockrell HM, Ottenhoff THM, Scriba TJ, Picker LJ, Walzl G, Kaufmann SHE, Zak DE; GC6-74 Consortium.

Front Immunol. 2019 Mar 22;10:527. doi: 10.3389/fimmu.2019.00527. eCollection 2019.

8.

Evidence for Highly Variable, Region-Specific Patterns of T-Cell Epitope Mutations Accumulating in Mycobacterium tuberculosis Strains.

Ramaiah A, Nayak S, Rakshit S, Manson AL, Abeel T, Shanmugam S, Sahoo PN, John AJUK, Sundaramurthi JC, Narayanan S, D'Souza G, von Hoegen P, Ottenhoff THM, Swaminathan S, Earl AM, Vyakarnam A.

Front Immunol. 2019 Feb 13;10:195. doi: 10.3389/fimmu.2019.00195. eCollection 2019.

9.

Optimisation, harmonisation and standardisation of the direct mycobacterial growth inhibition assay using cryopreserved human peripheral blood mononuclear cells.

Tanner R, Smith SG, van Meijgaarden KE, Giannoni F, Wilkie M, Gabriele L, Palma C, Dockrell HM, Ottenhoff THM, McShane H.

J Immunol Methods. 2019 Jun;469:1-10. doi: 10.1016/j.jim.2019.01.006. Epub 2019 Jan 31.

10.

Prevention of tuberculosis infection and disease by local BCG in repeatedly exposed rhesus macaques.

Dijkman K, Sombroek CC, Vervenne RAW, Hofman SO, Boot C, Remarque EJ, Kocken CHM, Ottenhoff THM, Kondova I, Khayum MA, Haanstra KG, Vierboom MPM, Verreck FAW.

Nat Med. 2019 Feb;25(2):255-262. doi: 10.1038/s41591-018-0319-9. Epub 2019 Jan 21.

PMID:
30664782
11.

Atypical Human Effector/Memory CD4+ T Cells With a Naive-Like Phenotype.

Caccamo N, Joosten SA, Ottenhoff THM, Dieli F.

Front Immunol. 2018 Dec 3;9:2832. doi: 10.3389/fimmu.2018.02832. eCollection 2018. Review.

12.

Metabolite changes in blood predict the onset of tuberculosis.

Weiner J 3rd, Maertzdorf J, Sutherland JS, Duffy FJ, Thompson E, Suliman S, McEwen G, Thiel B, Parida SK, Zyla J, Hanekom WA, Mohney RP, Boom WH, Mayanja-Kizza H, Howe R, Dockrell HM, Ottenhoff THM, Scriba TJ, Zak DE, Walzl G, Kaufmann SHE; GC6-74 consortium.

Nat Commun. 2018 Dec 6;9(1):5208. doi: 10.1038/s41467-018-07635-7.

13.

A Systematic Review on Novel Mycobacterium tuberculosis Antigens and Their Discriminatory Potential for the Diagnosis of Latent and Active Tuberculosis.

Meier NR, Jacobsen M, Ottenhoff THM, Ritz N.

Front Immunol. 2018 Nov 9;9:2476. doi: 10.3389/fimmu.2018.02476. eCollection 2018.

14.

NF-κB/MAPK activation underlies ACVR1-mediated inflammation in human heterotopic ossification.

Barruet E, Morales BM, Cain CJ, Ton AN, Wentworth KL, Chan TV, Moody TA, Haks MC, Ottenhoff TH, Hellman J, Nakamura MC, Hsiao EC.

JCI Insight. 2018 Nov 15;3(22). pii: 122958. doi: 10.1172/jci.insight.122958.

15.

Complement Component C1q as Serum Biomarker to Detect Active Tuberculosis.

Lubbers R, Sutherland JS, Goletti D, de Paus RA, van Moorsel CHM, Veltkamp M, Vestjens SMT, Bos WJW, Petrone L, Del Nonno F, Bajema IM, Dijkman K, Verreck FAW, Walzl G, Gelderman KA, Groeneveld GH, Geluk A, Ottenhoff THM, Joosten SA, Trouw LA.

Front Immunol. 2018 Oct 23;9:2427. doi: 10.3389/fimmu.2018.02427. eCollection 2018.

16.

Genome wide approaches discover novel Mycobacterium tuberculosis antigens as correlates of infection, disease, immunity and targets for vaccination.

Coppola M, Ottenhoff TH.

Semin Immunol. 2018 Oct;39:88-101. doi: 10.1016/j.smim.2018.07.001. Epub 2018 Jul 7. Review.

17.

Correlates of vaccine adjuvanticity, vaccine activity, protective immunity and disease in human infectious disease and cancer.

Ottenhoff THM.

Semin Immunol. 2018 Oct;39:1-3. doi: 10.1016/j.smim.2018.10.002. Epub 2018 Oct 11. No abstract available.

PMID:
30318307
18.

Cross-laboratory evaluation of multiplex bead assays including independent common reference standards for immunological monitoring of observational and interventional human studies.

van Meijgaarden KE, Khatri B, Smith SG, Drittij AMFH, de Paus RA, Goeman JJ, Ho MM, Dockrell HM, McShane H, Joosten SA, Ottenhoff THM.

PLoS One. 2018 Sep 4;13(9):e0201205. doi: 10.1371/journal.pone.0201205. eCollection 2018.

19.

Borderline QuantiFERON results and the distinction between specific responses and test variability.

Uzorka JW, Bossink AWJ, Franken WPJ, Thijsen SFT, Leyten EMS, van Haeften AC, Doornenbal G, Boonstra P, Ottenhoff THM, Arend SM.

Tuberculosis (Edinb). 2018 Jul;111:102-108. doi: 10.1016/j.tube.2018.06.002. Epub 2018 Jun 7.

20.

Host Gene Expression Kinetics During Treatment of Tuberculosis in HIV-Coinfected Individuals Is Independent of Highly Active Antiretroviral Therapy.

Gebremicael G, Kassa D, Quinten E, Alemayehu Y, Gebreegziaxier A, Belay Y, van Baarle D, Ottenhoff THM, Cliff JM, Haks MC.

J Infect Dis. 2018 Oct 20;218(11):1833-1846. doi: 10.1093/infdis/jiy404.

21.

Antibody glycosylation in inflammation, disease and vaccination.

Alter G, Ottenhoff THM, Joosten SA.

Semin Immunol. 2018 Oct;39:102-110. doi: 10.1016/j.smim.2018.05.003. Epub 2018 Jun 11. Review.

22.

Human CD4 T-Cells With a Naive Phenotype Produce Multiple Cytokines During Mycobacterium Tuberculosis Infection and Correlate With Active Disease.

Orlando V, La Manna MP, Goletti D, Palmieri F, Lo Presti E, Joosten SA, La Mendola C, Buccheri S, Ottenhoff THM, Dieli F, Caccamo N.

Front Immunol. 2018 May 23;9:1119. doi: 10.3389/fimmu.2018.01119. eCollection 2018.

23.

Impaired Immune Response to Primary but Not to Booster Vaccination Against Hepatitis B in Older Adults.

Weinberger B, Haks MC, de Paus RA, Ottenhoff THM, Bauer T, Grubeck-Loebenstein B.

Front Immunol. 2018 May 15;9:1035. doi: 10.3389/fimmu.2018.01035. eCollection 2018.

24.

Patients with Concurrent Tuberculosis and Diabetes Have a Pro-Atherogenic Plasma Lipid Profile.

Vrieling F, Ronacher K, Kleynhans L, van den Akker E, Walzl G, Ottenhoff THM, Joosten SA.

EBioMedicine. 2018 Jun;32:192-200. doi: 10.1016/j.ebiom.2018.05.011. Epub 2018 May 17.

25.

A novel view on the pathogenesis of complications after intravesical BCG for bladder cancer.

Bilsen MP, van Meijgaarden KE, de Jong HK, Joosten SA, Prins C, Kroft LJM, Jonker JT, Crobach S, Pelger RC, Ottenhoff THM, Arend SM.

Int J Infect Dis. 2018 Jul;72:63-68. doi: 10.1016/j.ijid.2018.05.006. Epub 2018 May 17.

26.

A Serum Circulating miRNA Signature for Short-Term Risk of Progression to Active Tuberculosis Among Household Contacts.

Duffy FJ, Thompson E, Downing K, Suliman S, Mayanja-Kizza H, Boom WH, Thiel B, Weiner Iii J, Kaufmann SHE, Dover D, Tabb DL, Dockrell HM, Ottenhoff THM, Tromp G, Scriba TJ, Zak DE, Walzl G; GC6-74 Consortium.

Front Immunol. 2018 Apr 13;9:661. doi: 10.3389/fimmu.2018.00661. eCollection 2018.

27.

Retinal Pigment Epithelial Cells Control Early Mycobacterium tuberculosis Infection via Interferon Signaling.

La Distia Nora R, Walburg KV, van Hagen PM, Swagemakers SMA, van der Spek PJ, Quinten E, van Velthoven M, Ottenhoff THM, Dik WA, Haks MC.

Invest Ophthalmol Vis Sci. 2018 Mar 1;59(3):1384-1395. doi: 10.1167/iovs.17-23246.

PMID:
29625462
28.

Four-gene Pan-African Blood Signature Predicts Progression to Tuberculosis.

Suliman S, Thompson E, Sutherland J, Weiner Rd J, Ota MOC, Shankar S, Penn-Nicholson A, Thiel B, Erasmus M, Maertzdorf J, Duffy FJ, Hill PC, Hughes EJ, Stanley K, Downing K, Fisher ML, Valvo J, Parida SK, van der Spuy G, Tromp G, Adetifa IMO, Donkor S, Howe R, Mayanja-Kizza H, Boom WH, Dockrell H, Ottenhoff THM, Hatherill M, Aderem A, Hanekom WA, Scriba TJ, Kaufmann SH, Zak DE, Walzl G; GC6-74 and ACS cohort study groups.

Am J Respir Crit Care Med. 2018 Apr 6. doi: 10.1164/rccm.201711-2340OC. [Epub ahead of print]

29.

Vaccines for Leprosy and Tuberculosis: Opportunities for Shared Research, Development, and Application.

Coppola M, van den Eeden SJF, Robbins N, Wilson L, Franken KLMC, Adams LB, Gillis TP, Ottenhoff THM, Geluk A.

Front Immunol. 2018 Feb 26;9:308. doi: 10.3389/fimmu.2018.00308. eCollection 2018. Review.

30.

Mycobacterial growth inhibition is associated with trained innate immunity.

Joosten SA, van Meijgaarden KE, Arend SM, Prins C, Oftung F, Korsvold GE, Kik SV, Arts RJ, van Crevel R, Netea MG, Ottenhoff TH.

J Clin Invest. 2018 May 1;128(5):1837-1851. doi: 10.1172/JCI97508. Epub 2018 Apr 3.

31.

Update on tuberculosis biomarkers: From correlates of risk, to correlates of active disease and of cure from disease.

Goletti D, Lee MR, Wang JY, Walter N, Ottenhoff THM.

Respirology. 2018 May;23(5):455-466. doi: 10.1111/resp.13272. Epub 2018 Feb 18. Review.

32.

Africa-wide evaluation of host biomarkers in QuantiFERON supernatants for the diagnosis of pulmonary tuberculosis.

Chegou NN, Sutherland JS, Namuganga AR, Corstjens PL, Geluk A, Gebremichael G, Mendy J, Malherbe S, Stanley K, van der Spuy GD, Kriel M, Loxton AG, Kriel B, Simukonda F, Bekele Y, Sheehama JA, Nelongo J, van der Vyver M, Gebrexabher A, Hailu H, Esterhuyse MM, Rosenkrands I, Aagard C, Kidd M, Kassa D, Mihret A, Howe R, Cliff JM, Crampin AC, Mayanja-Kizza H, Kaufmann SHE, Dockrell HM, Ottenhoff THM, Walzl G; AE-TBC consortium.

Sci Rep. 2018 Feb 8;8(1):2675. doi: 10.1038/s41598-018-20855-7.

33.

IgA and IgG against Mycobacterium tuberculosis Rv2031 discriminate between pulmonary tuberculosis patients, Mycobacterium tuberculosis-infected and non-infected individuals.

Abebe F, Belay M, Legesse M, K L M C F, Ottenhoff THM.

PLoS One. 2018 Jan 26;13(1):e0190989. doi: 10.1371/journal.pone.0190989. eCollection 2018.

34.

Combined chemical genetics and data-driven bioinformatics approach identifies receptor tyrosine kinase inhibitors as host-directed antimicrobials.

Korbee CJ, Heemskerk MT, Kocev D, van Strijen E, Rabiee O, Franken KLMC, Wilson L, Savage NDL, Džeroski S, Haks MC, Ottenhoff THM.

Nat Commun. 2018 Jan 24;9(1):358. doi: 10.1038/s41467-017-02777-6.

35.

Tuberculosis vaccines: Opportunities and challenges.

Zhu B, Dockrell HM, Ottenhoff THM, Evans TG, Zhang Y.

Respirology. 2018 Apr;23(4):359-368. doi: 10.1111/resp.13245. Epub 2018 Jan 17. Review.

36.

Potential of DosR and Rpf antigens from Mycobacterium tuberculosis to discriminate between latent and active tuberculosis in a tuberculosis endemic population of Medellin Colombia.

Arroyo L, Marín D, Franken KLMC, Ottenhoff THM, Barrera LF.

BMC Infect Dis. 2018 Jan 8;18(1):26. doi: 10.1186/s12879-017-2929-0.

37.

Molecular Signatures of Immunity and Immunogenicity in Infection and Vaccination.

Haks MC, Bottazzi B, Cecchinato V, De Gregorio C, Del Giudice G, Kaufmann SHE, Lanzavecchia A, Lewis DJM, Maertzdorf J, Mantovani A, Sallusto F, Sironi M, Uguccioni M, Ottenhoff THM.

Front Immunol. 2017 Nov 15;8:1563. doi: 10.3389/fimmu.2017.01563. eCollection 2017. Review.

38.

Proof of concept that most borderline Quantiferon results are true antigen-specific responses.

Uzorka JW, Kroft LJM, Bakker JA, van Zwet EW, Huisman E, Knetsch-Prins C, van der Zwan CJ, Ottenhoff THM, Arend SM.

Eur Respir J. 2017 Nov 16;50(5). pii: 1701630. doi: 10.1183/13993003.01630-2017. Print 2017 Nov. No abstract available.

39.

Detailed characterization of human Mycobacterium tuberculosis specific HLA-E restricted CD8+ T cells.

Prezzemolo T, van Meijgaarden KE, Franken KLMC, Caccamo N, Dieli F, Ottenhoff THM, Joosten SA.

Eur J Immunol. 2018 Feb;48(2):293-305. doi: 10.1002/eji.201747184. Epub 2017 Dec 15.

40.

TBVAC2020: Advancing Tuberculosis Vaccines from Discovery to Clinical Development.

Kaufmann SHE, Dockrell HM, Drager N, Ho MM, McShane H, Neyrolles O, Ottenhoff THM, Patel B, Roordink D, Spertini F, Stenger S, Thole J, Verreck FAW, Williams A; TBVAC2020 Consortium.

Front Immunol. 2017 Oct 4;8:1203. doi: 10.3389/fimmu.2017.01203. eCollection 2017. Review.

41.

The SysteMHC Atlas project.

Shao W, Pedrioli PGA, Wolski W, Scurtescu C, Schmid E, Vizcaíno JA, Courcelles M, Schuster H, Kowalewski D, Marino F, Arlehamn CSL, Vaughan K, Peters B, Sette A, Ottenhoff THM, Meijgaarden KE, Nieuwenhuizen N, Kaufmann SHE, Schlapbach R, Castle JC, Nesvizhskii AI, Nielsen M, Deutsch EW, Campbell DS, Moritz RL, Zubarev RA, Ytterberg AJ, Purcell AW, Marcilla M, Paradela A, Wang Q, Costello CE, Ternette N, van Veelen PA, van Els CACM, Heck AJR, de Souza GA, Sollid LM, Admon A, Stevanovic S, Rammensee HG, Thibault P, Perreault C, Bassani-Sternberg M, Aebersold R, Caron E.

Nucleic Acids Res. 2018 Jan 4;46(D1):D1237-D1247. doi: 10.1093/nar/gkx664.

42.

Circulating Mycobacterium tuberculosis DosR latency antigen-specific, polyfunctional, regulatory IL10+ Th17 CD4 T-cells differentiate latent from active tuberculosis.

Rakshit S, Adiga V, Nayak S, Sahoo PN, Sharma PK, van Meijgaarden KE, Uk J AJ, Dhar C, Souza GD, Finak G, De Rosa SC, Ottenhoff THM, Vyakarnam A.

Sci Rep. 2017 Sep 20;7(1):11948. doi: 10.1038/s41598-017-10773-5.

43.

Mechanisms behind TB, HBV, and HIV chronic infections.

Durantel D, Kusters I, Louis J, Manel N, Ottenhoff THM, Picot V, Saaadatian-Elahi M.

Infect Genet Evol. 2017 Nov;55:142-150. doi: 10.1016/j.meegid.2017.09.008. Epub 2017 Sep 13.

PMID:
28919545
44.

South Asian men have lower expression of IFN signalling genes in white adipose tissue and skeletal muscle compared with white men.

van Dam AD, Hanssen MJW, van Eenige R, Quinten E, Sips HC, Hülsman CJM, Jazet IM, van Marken Lichtenbelt WD, Ottenhoff THM, Haks MC, Rensen PCN, Boon MR.

Diabetologia. 2017 Dec;60(12):2525-2528. doi: 10.1007/s00125-017-4427-8. Epub 2017 Sep 8. No abstract available.

PMID:
28887664
45.

Immunological characterization of latent tuberculosis infection in a low endemic country.

de Paus RA, van Meijgaarden KE, Prins C, Kamphorst MH, Arend SM, Ottenhoff THM, Joosten SA.

Tuberculosis (Edinb). 2017 Sep;106:62-72. doi: 10.1016/j.tube.2017.07.001. Epub 2017 Jul 4.

PMID:
28802407
46.

Differences in IgG responses against infection phase related Mycobacterium tuberculosis (Mtb) specific antigens in individuals exposed or not to Mtb correlate with control of TB infection and progression.

Coppola M, Arroyo L, van Meijgaarden KE, Franken KL, Geluk A, Barrera LF, Ottenhoff THM.

Tuberculosis (Edinb). 2017 Sep;106:25-32. doi: 10.1016/j.tube.2017.06.001. Epub 2017 Jun 8.

47.

Novel transcriptional signatures for sputum-independent diagnostics of tuberculosis in children.

Gjøen JE, Jenum S, Sivakumaran D, Mukherjee A, Macaden R, Kabra SK, Lodha R, Ottenhoff THM, Haks MC, Doherty TM, Ritz C, Grewal HMS.

Sci Rep. 2017 Jul 19;7(1):5839. doi: 10.1038/s41598-017-05057-x.

48.

The effects of a psychological intervention directed at optimizing immune function: study protocol for a randomized controlled trial.

Schakel L, Veldhuijzen DS, van Middendorp H, Prins C, Joosten SA, Ottenhoff THM, Visser LG, Evers AWM.

Trials. 2017 May 26;18(1):243. doi: 10.1186/s13063-017-1983-7.

49.

Long-lasting tuberculous pleurisy.

Petruccioli E, Scriba TJ, Petrone L, Hatherill M, Cirillo DM, Joosten SA, Codecasa LR, Ottenhoff TH, Denkinger CM, Goletti D.

Eur Respir J. 2017 May 25;49(5). pii: 1700356. doi: 10.1183/13993003.00356-2017. Print 2017 May. No abstract available.

50.

MHC Ib molecule Qa-1 presents Mycobacterium tuberculosis peptide antigens to CD8+ T cells and contributes to protection against infection.

Bian Y, Shang S, Siddiqui S, Zhao J, Joosten SA, Ottenhoff THM, Cantor H, Wang CR.

PLoS Pathog. 2017 May 5;13(5):e1006384. doi: 10.1371/journal.ppat.1006384. eCollection 2017 May.

Supplemental Content

Loading ...
Support Center